期刊文献+

Predicting prognosis of rectal cancer patients with total mesorectal excision using molecular markers 被引量:10

Predicting prognosis of rectal cancer patients with total mesorectal excision using molecular markers
下载PDF
导出
摘要 AIM:To explore the prognostic variables in rectal cancer patients undergoing curative total mesorectal excision and the effect of postoperative chemotherapy in advanced rectal cancer. METHODS:A total of 259 consecutive rectal cancer patients treated with curative total mesorectal excision between 1999 and 2004 were collected. p53,p21,PCNA,and CD44v6 were examined using immunohistochemistry (IHC). The correlation between clinicopathological or molecular variables and clinical outcomes,including local recurrence,metastasis,disease-free survival and overall survival,was analyzed. RESULTS:The median follow-up was 44 mo. Five-year survival rates and 5-year disease free survival rates were 75.43% and 70.32%,respectively. Multi-analysis revealed TNM staging,preoperative CEA,and CD44v6 level were independent risk factors predicting overall survival or disease free survival. The hazard ratio of peroperative CEA was 2.65 (95% CI 1.4-5) and 3.10 (95% CI 1.37-6.54) for disease free survival and overall survival,respectively. The hazard ratio of CD44v6 was 1.93 (95% CI 1.04-3.61) and 2.21 (95% CI 1.01-4.88) for disease free survival and overall survival,respectively. TNM staging was the only risk factor predicting local recurrence. Postoperative chemotherapy without radiotherapy did not improve patients' outcome. CONCLUSION:TNM staging,preoperative CEA and CD44v6 were independent prognostic factors for rectal cancer patients with total mesorectal excision. Postoperative chemotherapy may be only used together with radiotherapy for rectal cancer patients. AIM:To explore the prognostic variables in rectal cancer patients undergoing curative total mesorectal excision and the effect of postoperative chemotherapy in advanced rectal cancer. METHODS:A total of 259 consecutive rectal cancer patients treated with curative total mesorectal excision between 1999 and 2004 were collected. p53,p21,PCNA,and CD44v6 were examined using immunohistochemistry (IHC). The correlation between clinicopathological or molecular variables and clinical outcomes,including local recurrence,metastasis,disease-free survival and overall survival,was analyzed. RESULTS:The median follow-up was 44 mo. Five-year survival rates and 5-year disease free survival rates were 75.43% and 70.32%,respectively. Multi-analysis revealed TNM staging,preoperative CEA,and CD44v6 level were independent risk factors predicting overall survival or disease free survival. The hazard ratio of peroperative CEA was 2.65 (95% CI 1.4-5) and 3.10 (95% CI 1.37-6.54) for disease free survival and overall survival,respectively. The hazard ratio of CD44v6 was 1.93 (95% CI 1.04-3.61) and 2.21 (95% CI 1.01-4.88) for disease free survival and overall survival,respectively. TNM staging was the only risk factor predicting local recurrence. Postoperative chemotherapy without radiotherapy did not improve patients' outcome. CONCLUSION:TNM staging,preoperative CEA and CD44v6 were independent prognostic factors for rectal cancer patients with total mesorectal excision. Postoperative chemotherapy may be only used together with radiotherapy for rectal cancer patients.
出处 《World Journal of Gastroenterology》 SCIE CAS CSCD 2007年第21期3009-3015,共7页 世界胃肠病学杂志(英文版)
关键词 Rectal cancer Total mesorectal excision IMMUNOHISTOCHEMISTRY Disease free survival p53 P21 PCNA CD44V6 CEA PROGNOSIS 直肠癌 分子标记 预后 全切除术 免疫组织化学
  • 相关文献

参考文献14

  • 1Marja Hilska M.D.,Yrj??U. Collan M.D.,?Ph.D.,?F.R.C.Path.,V.?Jukka Laine M.D.,?Ph.D.,Jyrki K?ssi M.D.,?Ph.D.,Pirkko Hirsim?ki Ph.D.,Matti Laato M.D.,?Ph.D.,Peter?J. Roberts M.D.,?Ph.D.The Significance of Tumor Markers for Proliferation and Apoptosis in Predicting Survival in Colorectal Cancer[J].Diseases of the Colon & Rectum.2005(12)
  • 2M. Morgan,D. Koorey,D. Painter,M. Findlay,R. Newland,P. Chapuis,M. Solomon.p53 and DCC immunohistochemistry in curative rectal cancer surgery[J].International Journal of Colorectal Disease.2003(3)
  • 3Jyotsna M. Bhatavdekar Ph.D.,Devendra D. Patel M.S.,Priya R. Chikhlikar Ph.D.,Dr. Neelam G. Shah Ph.D.,Hemangini H. Vora Ph.D.,Nandita Ghosh Ph.D.,Trupti I. Trivedi M.Sc.Molecular markers are predictors of recurrence and survival in patients with Dukes B and Dukes C colorectal adenocarcinoma[J].Diseases of the Colon & Rectum.2001(4)
  • 4Tomomi Ishida.Immunohistochemical Expression of the CD44 Variant 6 in Colorectal Adenocarcinoma[J].Surgery Today.2000(1)
  • 5Kammerer U,Kapp M,Gassel AM,Richter T,Tank C,Dietl J,Ruck P.A new rapid immunohistochemical staining technique using the EnVision antibody complex[].Journal of Histochemistry and Cytochemistry.2001
  • 6Stauder R,Eisterer W,Thaler J,Gunthert U.CD44 variant isoforms in non-Hodgkin’s lymphoma: a new independent prognostic factor[].Blood.1995
  • 7Dahlberg M,Glimelius B,Pahlman L.Changing strategy for rectal cancer is associated with improved outcome[].British Journal of Surgery.1999
  • 8Yong-Jun Liu,Pei-Song Yan,Jun Li,Jing-Fen Jia.Expression and significance of CD44s, CD44v6, and nm23 mRNA in human cancer[J].World Journal of Gastroenterology,2005,11(42):6601-6606. 被引量:63
  • 9Herrlich P,Pals S,Ponta H.CD44 in colon cancer[].European Journal of Cancer.1995
  • 10Neoptolemos JP,Oates GD,Newbold KM,Robson AM,McConkey C,Powell J.Cyclin/proliferation cell nuclear antigen immunohistochemistry does not improve the prognostic power of Dukes’ or Jass’ classifications for colorectal cancer[].British Journal of Surgery.1995

二级参考文献4

共引文献62

同被引文献49

引证文献10

二级引证文献36

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部